MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)

NCT04509791 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

114

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Mellitus, Type 1

Interventions

DRUG: Anti-Human Thymocyte Immunoglobulin, Rabbit

Sponsor

Universitaire Ziekenhuizen KU Leuven